SY
Syngene International Limited
SYNGENE.NS · NSE
₹369.65 +6.40% (+₹22.25)
1M -8.30%
Market Cap ₹139.3B
P/E Ratio 63.03x
Div. Yield 0.36%
ROE 4.60%
Bulios Fair Price
₹315.86
14.6% downside
Current Price
₹369.65
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SYNGENE.NS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
32 /100
Expensive P/S 3.87x
P/E 63.03x
P/B 2.86x
Growth
50 /100
Stable FCF growth 26.05%
EPS growth 11.90%
Book val. growth 10.18%
Profitability
37 /100
Moderate Op. margin 12.64%
Gross margin 32.49%
FCF margin 5.56%
Quality
31 /100
Poor ROA 3.28%
ROIC 6.28%
Asset turnover 0.53x
Debt
92 /100
Low Int. coverage 8.02x
Debt/Equity 0.10x
Net debt/EBITDA 0.39x
Stability
68 /100
Stable EPS volatility 23.98%
Beta 0.08x
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SYNGENE.NS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Siddharth Mittal
Employees
6,692
Headquarters
Bengaluru
Upcoming events
27 OCT
Earnings
Upcoming earnings report